A Galician Lung Cancer Group phase II study of bevacizumab (B), cisplatin, and vinorelbine in chemotherapy-naive patients (p) with non-squamous non-small cell lung cancer (NSCLC).
2010
e18052 Background: Bevacizumab, an anti-VEGF monoclonal antibody, improves response rates and prolongs survival in p with non squamous NSCLC when combined with carboplatin-paclitaxel and PFS when c...
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
1
Citations
NaN
KQI